What's in Nova Scotia Health Authority's pipeline?

Nova Scotia Health Authority has 10 drugs in our index: 7 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Nova Scotia Health Authority's portfolio?

Top competitors by shared drug class: Centre Hospitalier Universitaire de Nīmes, Prisma Health-Upstate, Kuopio University Hospital, Ain Shams University, Alza Corporation, DE, USA.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/nova-scotia-health-authority.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Nova Scotia Health Authority — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nova Scotia Health Authority pipeline: 7 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 2 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Controlled Release Morphine	Controlled Release Morphine	marketed	Opioid analgesic	Mu-opioid receptor (μ-opioid receptor)	Pain Management
Fleet Enema	Fleet Enema	marketed
Prostagladin	Prostagladin	marketed			Other
Chloroprocaine Injection	Chloroprocaine Injection	marketed	Local anesthetic (ester)	Voltage-gated sodium channels	Anesthesia
Mepivacaine Injection	Mepivacaine Injection	marketed	Local anesthetic (amide)	Voltage-gated sodium channels	Anesthesia
TCA	TCA	marketed	Tricyclic antidepressant	Norepinephrine transporter (NET), Serotonin transporter (SERT)	Psychiatry, Pain Management
Aggressive Blood Pressure control	Aggressive Blood Pressure control	marketed
acetaminophen plus ibuprofen	acetaminophen plus ibuprofen	phase 3	NSAID	COX-2	Pain management
acetaminophen plus codeine	acetaminophen plus codeine	phase 3	Opioid analgesic	Opioid receptors	Pain management

Therapeutic area mix

Anesthesia · 2
Pain management · 2
Other · 1
Pain Management · 1
Psychiatry, Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Centre Hospitalier Universitaire de Nīmes · 2 shared drug classes
Prisma Health-Upstate · 2 shared drug classes
Kuopio University Hospital · 2 shared drug classes
Ain Shams University · 1 shared drug class
Alza Corporation, DE, USA · 1 shared drug class
American Genomics, LLC · 1 shared drug class
Allergan · 1 shared drug class
American University of Beirut Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Nova Scotia Health Authority:

Cite this brief

Drug Landscape (2026). Nova Scotia Health Authority — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nova-scotia-health-authority. Accessed 2026-05-17.